CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
bevacizumab [Avastin] +2 moredrug
Likely dose
bevacizumab [Avastin] 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01159171
NCT01159171Phase 2Completed
CompareCT.gov

Phase II Study of the Combination of Bevacizumab (rhuMab VEGF) and Oxaliplatin Plus Capecitabine (XELOX) in Patients With Advanced Colorectal Cancer

Hoffmann-La Roche·interventional·Posted Jul 9, 2010·Updated Aug 15, 2014

In Brief

A Phase 2 clinical trial evaluating bevacizumab [Avastin], capecitabine [Xeloda], and 1 other intervention for Colorectal Cancer. Completed, enrolled 50 participants across 6 sites.

Detailed Summary

This study will assess the efficacy and safety of treatment with the combination Avastin (bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d. on Days 1-14 of every 28-day cycle and oxaliplatin 40mg/m2 iv weekly in patients with inoperable locally advanced or metastatic colorectal cancer. The anticipated time on study treatment is until disease progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 9, 2010
Enrollment StartJan 1, 2006
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 16.0 years ago

Interventions

bevacizumab [Avastin]drug

5 mg/kg intravenously every 14 days

capecitabine [Xeloda]drug

1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle

oxaliplatindrug

40 mg/m2 iv weekly